left-arrow right-arrow pinterest facebook google_plus linkedin

Blood Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the trial ID number listed with the description.


Alliance A041701

Status: Recruiting | Phase II/III

Official Title: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Study Purpose: To compare the usual treatment alone to using uproleselan plus the usual treatment. Learn more


Alliance A041702

Status: Recruiting | Phase III 

Official Title: A Randomized Phase III study of Ibrutinib Plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 years of age) with Chronic Lymphocytic Leukemia (CLL)

Study Purpose: To compare the usual treatment alone (Ibrutinib plus Obinutuzumab) to using Venetoclax plus the usual treatment. The addition of Venetoclax to the usual treatment could prevent your chronic lymphocytic leukemia from returning. Learn more


CIBMTR Research Database

Status: Recruiting | Phase Not Applicable 

Official Title: Center for International Blood and Marrow Transplant Research: Protocol for a Research Database for Hematopoietic Cell Transplantation and Cellular Therapies

Study Purpose: To gather health information from patients receiving stem cell transplants that can be used to find ways to make stem cell transplants work better. Learn more


SWOG S1712

Status: Recruiting | Phase II

Official Title: A randomized phase II study of ruxolitinib (NCS-752295) in combination with BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia (CML) patients with molecular evidence of disease.  

Study Purpose: The purpose of this study is to compare the good and bad effects of adding the study drug ruxolitinib to the usual chemotherapy (called TKI, which is either dasatinib or nilotinib) with the good and bad effects of using TKI alone. Learn more